MIRA INFORM REPORT
|
Report Date : |
02.01.2007 |
IDENTIFICATION DETAILS
|
Name : |
CADILA
PHARMACEUTICALS LIMITED |
|
|
|
|
Formerly Known As : |
NOVA
BIOTECH PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Cadila Corporate Campus,
Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat, India |
|
|
|
|
Financials (as on) : |
31.03.2005 |
|
|
|
|
Date of Incorporation : |
28.02.1991 |
|
|
|
|
Com. Reg. No.: |
04-15132 |
|
|
|
|
CIN No.: [Company Identification No.] |
U24231GJ1991PTC015132 |
|
|
|
|
TAN No.: [Tax Deduction & Collection Account No.] |
AHMC0038ID |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACC6251E |
|
|
|
|
Legal Form : |
Private Limited Liability
Company |
|
|
|
|
Line of Business : |
Manufacturer,
Seller, Importer and Exporter of Hospital Disposables including Fiberglass
casting, Diagnostics, Pharmaceutical Machinery Manufacturers, Animal Health
Formulations and Feed Supplements, Agro Business, Plant Tissue Culture, and
Bio Fertilizers, Information Technology, Travel Business, Pharmaceutical
Products from Basic Chemicals and Bulk Drugs to intermediates and finished formulations. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
RATING
|
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is
considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 4500000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well
established company having fine track. Directors are reported as experienced,
respectable and resourceful businessmen. Their trade relations are fair.
Payments are usually correct and as per commitments. The
company can be considered normal for business dealings at usual trade terms
and conditions. |
LOCATIONS
|
Registered Office : |
Cadila Corporate Campus,
Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat |
|
Tel. No.: |
91-79-23825001(15
Lines) |
|
Fax No.: |
91-79-23825039 |
|
E-Mail : |
purchase@cadilapharma.com (For
Material Details) branded @cadilapharma.com (For Product Information) international@cadilapharma.com
(For International Business) website@cadilapharma.com |
|
Area : |
44 acres |
|
Location : |
Owned |
|
|
|
|
Head Office : |
Cadila Corporate Campus,
Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat |
|
Tel. No.: |
91-79-23825001(15
Lines) |
|
Fax No.: |
91-79-23825039 |
|
E-Mail : |
purchase@cadilapharma.com (For
Material Details) branded @cadilapharma.com (For Product Information) international@cadilapharma.com
(For International Business) website@cadilapharma.com |
|
|
|
|
Corporate Office : |
IRMA House, Off C. G. Road,
Navrangpura, Ahmedabad - 380 009, Gujarat, India |
|
Tel. No.: |
91-79-26562615 (5 lines) |
|
Fax No.: |
91-79-26425741 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
5000 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 1 : |
Dholka – Manufacturing
Plant Survey No. 1389, Trasad
Road, Dholka, Ahmedabad – 387 810,
Gujarat Tel. No. 91-79-23421841/83/84/3422006/7/8/9/10 Fax No. 91-79-23420315/3421220 Area : 50000 sq. ft. Location : Owned Chemicals SBU – Factory Plot No. 274, GIDC
Industrial Estate, Ankleshwar, Gujarat Tel. No. 91-2646-223846 / 252626 / 251519 Fax No. 91-2646-250051 Area : 174557 sq. ft. Location : Owned CHPL – Factory (Associated
Company) Survey No. 342, Nani Kadi,
Taluka Kadi, District Mehsana, North Gujarat Tel. No. 91-2764-262463 /
242037 / 242194 Fax No. 91-2764-242223 Location : Owned Karnavati Engineering
Limited (Associated Company) Survey No. 342, Nani Kadi,
Taluka Kadi, District Mehsana, North Gujarat Tel. 91-2764-262463 /
242037 / 242194 Fax. 91-2764-242608 Location : Owned Tissu Culture Lab 756, Prakruti Farm, Hirapur
Chowkdi, Hirapur, Ahmedabad, Gujarat Tel. No.
91-79-3855260/3855495/496 Location : Owned IRMA House, Off C. G. Road,
Navrangpura, Ahmedabad - 380 009, Gujarat, India Tel. No. 91-79-6562615 (5
lines) Fax. No. 91-79-6425741 Area : 5000 sq. ft. Location : Owned |
DIRECTORS
|
Name : |
Mr. Indravadan Ambalal
Modi |
|
Designation : |
Chairman and Managing
Director |
|
Address : |
"KAKABA", 13,
Sanjay Building, New Sharda Mandir Road, Paldi, Ahmedabad – 380 007, Gujarat |
|
Date of Birth/Age : |
18th February,
1926 |
|
Qualification : |
B. Sc. (Technical), Ph.D.
(Biology), Chemical Engineer from USA |
|
Experience : |
50 years |
|
Date of Joining : |
28.02.1991 |
|
Other Directorships:- |
1. Casil Health Products Limited - Chairman 2. Karnavati Engineering Limited – Chairman 3. Indian Research Manifestation Laboratories (Private)
Limited (IRM Lab) – Chairman 4. Green Challel
Travel Services – Director 5. IRM Investment Private Limited – Trustee 6. IRM Trust |
|
Profile
:- |
He
is a Founder Director of the erstwhile Indian Pharmaceutical major company,
now restructured as company. He
obtained his Bachelor’s degree in Science from the Baroda College in 1948.
Thereafter, he specialized in Technology in Pharmaceuticals and Fine
Chemicals at the university of Mumbai. As part of its’ Golden Jubilee
Celebrations in 1985, University of Mumbai, Department of Chemical
Technology, honoured Mr. Modi as its’ Alumni for his excellence of
performance in his chosen area. He
is revered as th champion of Indian Pharmaceutical Industry attaining its’
present global status. He
has been effectively representing the cause of National Pharmaceutical
Industry at various for a. As President of Indian Drug Manufacturer’s Association
(IDMA) and Chairman of Basic Chemical, Pharmaceuticals and Cosmetics Export
Promotion Council (CHEMEXCIL), his contributions are widely acclaimed in the
industry circle. He
is presented the National Working Group on Patent Laws, India (NWGP) and
Indian Drug Manufacturers’ Association (IDMA) on the subject ‘Patent Regime’
proposed in the Uruguay Round at Delhi from September 2-4, 1993. This
international conference was jointly sponsored by the Association of
Latinoamericana De Industries Pharmaceuticals (ALIFAR, Argentina) and the
Canadian Drug Manufacturer’s Association (CDMA, Canada) alongwith NWGPL and
IDMA. |
|
|
|
|
Name : |
Dr. Rajiv I. Modi |
|
Designation : |
Managing Director |
|
Address : |
"KAKABA", 13,
Sanjay Building, New Sharda Mandir Road, Paldi, Ahmedabad – 380 007, Gujarat |
|
Date of Birth/Age : |
09th May, 1960 |
|
Qualification : |
Ph. D. in Biological Science
|
|
Other Directorships:- |
·
Casil Health Products
Limited, Ahmedabad, Gujarat ·
Karnavati Engineering
Limited, Ahmedabad, Gujarat ·
Tissue Culture Laboratories,
Ahmedabad, Gujarat ·
Green Channel Travel
Services Private Limited |
|
Profile
:- |
He has awarded Genetics
Society of America’s Best Scientific Poster at the International Genetics
Congress held in August 1988 by the Genetics Society of America. Invited participant and
speaker at the Gordan Research Microbial Evolution and Population Biology in
July 1989 at Plymouth State of College, New Hampshire, USA Presented papers on various
aspects of Chemical Engineering, Biochemical Engineering and Biotechnology at
Different Institutes in India and abroad. He is being a qualified
Biotechnologist has charted out a visionary patha nd company is one of the
leading companies making significant investments in the area of
Biotechnology. Broadly the areas are Vaccines (Typhoid, Hepatitis ‘B’
Streptokinase etc). Biotherauptics (Hyaluronic Acid), Diagnostics (HIV Kits,
Hepatitis ‘C’ diagnostics Kits), PlantTissue Culture (transgenic plants –
tomato), Tissure Culture – potato). |
|
|
|
|
Name : |
Mr. Atul Tandon |
|
Designation : |
Director (w.e.f.
04.07.2003) |
|
|
|
|
Name : |
Mr. D. N. Khurana |
|
Designation : |
Director (w.e.f.
04.07.2003) |
|
|
|
|
Name : |
Mrs. Rashmi K. Mankodi |
|
Designation : |
Company Secretary (ACS) |
|
|
|
|
Name : |
Mrs. Shilaben I Modi |
|
Designation : |
Director |
|
|
|
|
Name : |
Mrs. Monika Garware Modi |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Chinubhai R Shah |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Pradip Khandwal |
|
Designation : |
Director |
KEY EXECUTIVES
|
Name : |
Mr. Michael W. Eggleston |
|
Designation : |
Chief Financial Officer /
Treasurer of the company |
|
|
|
|
Name : |
Mr. Andrej Gasperlin |
|
Designation : |
Vice President
(Pharmaceuticals) |
|
|
|
|
Name : |
Mr. Sherry Newton |
|
Designation : |
Logistics Manager |
|
|
|
|
Name : |
Mr. Juan C. Gonzalez |
|
Designation : |
Vice President (Latin
America) |
MAJOR SHAREHOLDERS
|
Names of Shareholders |
No. of Shares |
Percentage of Holding |
|
|
|
|
|
Mr. Indravadan A. Modi |
848600 |
5.66 |
|
Mr. Rajiv I. Modi |
848600 |
5.66 |
|
Mrs. Shilaben I. Modi |
848600 |
5.66 |
|
I. A. Modi Trust |
5940000 |
39.60 |
|
I. A. Modi – as Partner |
6514200 |
43.42 |
|
Total |
15000000 |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer,
Seller, Importer and Exporter of Hospital Disposables including Fiberglass
casting, Diagnostics, Pharmaceutical Machinery Manufacturers, Animal Health
Formulations and Feed Supplements, Agro Business, Plant Tissue Culture, and
Bio Fertilizers, Information Technology, Travel Business, Pharmaceutical
Products from Basic Chemicals and Bulk Drugs to intermediates and finished
formulations. |
||||||||
|
|
|
||||||||
|
Products : |
Its’ products range
includes :- v
Cardiovascular Drugs v
Gastrointestinal Drugs v
Anti
Inflammatory/Analgesic Drugs v
Antibiotics/Anti
Infectives v
Vaccines/Immunomodulators v
Anti-Diabetic Drugs v
Vitamins /
Haemantinics v
Psychiatric Agents/CNS
Drugs v
Haemostatics v
Antihistamines/Anti
Allergic Drugs v
Anti-Aids (Anti
Retroviral) Therapy v
Anti-Cancer
(Cytotoxic) Drugs v
Ophthalmic Drugs v
Veterinary Products v
Expectorants/Bronchodilators v
Anti-Asthmatic Drugs v
Herabal Products |
||||||||
|
|
|
||||||||
|
Brand Names : |
‘
ACILOC’, ‘ENVAS MICOBUTAL’, ‘ CLAX’, ‘ ZASO’, ‘ NODON’, ‘HAEMUP’, ‘LMX’,
‘SYMBIOTEK’, ‘LEPROSY’, ‘RABELOC’, ‘IMMUNO’,
‘MODALATOR’, ‘LEPROVAC’, ‘MONTELAST’.
|
||||||||
|
|
|
||||||||
|
Exports to : |
Romania,
Russia, Srilanka, Malawi, Kenya, Thailand, Australia, China |
||||||||
|
|
|
||||||||
|
Imports from : |
Europe,
Japan, China and U.S.A. |
||||||||
|
|
|
||||||||
|
Terms : |
|
||||||||
|
|
|
||||||||
|
Selling terms : |
L/C,
Local Cash and Credit basis |
||||||||
|
|
|
||||||||
|
Purchasing : |
L/C,
Local Cash and Credit (180 days) basis
|
PRODUCTION STATUS
|
Particulars |
Unit |
Actual Production |
|
Tablets |
ML. Nos. |
3900 |
|
Capsules |
ML. Nos. |
150 |
|
Liquids |
K. litres |
6000 |
|
Sterile Vials |
Millions |
84 |
|
Ampoules |
Millions |
84 |
|
Granules |
Tonnes |
15.06 |
|
Dry Sterile Vials |
Millions |
48 |
|
Dry Syrup Bottles |
Millions |
27 |
GENERAL INFORMATION
|
Customers : |
§
Buying Agents §
Distributors §
Clinics §
Hospitals §
Manufacturers §
Retailers §
Wholesalers Some
of major customer includes: §
Apollo Hospital §
Sal Hospital §
Krishna Heart Hospital
§
Government Hospitals |
||||||||||||
|
|
|
||||||||||||
|
No. of Employees : |
Around
3800
|
||||||||||||
|
|
|
||||||||||||
|
Bankers : |
Ø
Bank of Baroda Ashram
Road Branch, Ahmedabad-380
009, Gujarat Ø
Corporation Bank Navrangpura
Branch, Ahmedabad,
Gujarat Ø
Oriental Bank of
Commerce Ashram
Road, Ahmedabad, Gujarat Ø
Punjab National Bank Ashram
Road Branch, Ahmedabad – 380 009, Gujarat Ø
Union Bank of India Ahmedabad,
Gujarat Ø
UTI Bank Limited Ahmedabad,
Gujarat Ø
Syndicate Bank Navrangpura,
Ahmedabad, Gujarat Ø
ICICI Bank Bandra,
Mumbai, Maharashtra |
||||||||||||
|
|
|
||||||||||||
|
Facilities : |
Oriental
Bank of Commerce - The company enjoys hypothecation facility of Rs. 10.000
millions dated 06.04.2000 from its'
bankers. UTI
Bank Limited - The company enjoys hypothecation facility of Rs. 780.000
millions from its' bankers. Syndicate
Bank - The company enjoys hypothecation facility of Rs. 1.400 millions dated
06.04.2000 from its' bankers. ICICI
Bank - The company enjoys hypothecation facility of Rs. 300.000 millions
dated 06.04.2000 from its' bankers.) |
|
|
|
|
Banking Relations : |
Good |
|
|
|
|
Auditors : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address: |
3rd Floor,
‘Heritage’, Near Gujarat Vidhyapith, Off Ashram Road, Ahmedabad – 380 014,
Gujarat |
|
Tel. No.: |
91-79-7582542/7582543 |
|
Fax No.: |
91-79-7582551 |
|
E-Mail : |
|
|
|
|
|
Associates/Subsidiaries
: |
Ø
Casil Health Products
Limited, Ahmedabad, Gujarat Website: http://www.casilhealth.com Ø
Tissue Culture
Laboratories, Ahmedabad, Gujarat Ø
Green Channel Travel
Services Private Limited, Ahmedabad, Gujarat - The Local Agent for American Express Travel Related Services at Ahmedabad Ø
Karnavati America Ø
CPL Inc., USA Ø
Be-Tabs
Pharmaceuticals (Pty) Limited Ø
CPL – Alliance (South
Africa) Ø
Cadila (Nigeria)
Limited Ø
Cadila Pharmaceuticals
(E.A.) Limited Ø
IRM Investment Private
Limited Ø
Indian Research
Manifestation Laboratories (Private) Limited Ø
IRM Trust Ø
IRM Labs Limited Ø
Karnavati Engineering
Limited, Ahmedabad, Gujarat Website: http://www.karnavatiengineering.com
Ø
Wilnet Communication
Private Limited Website:
http://www.wilnetonline.net / www.willcall.wilnetonline.net Ø
Cadila Overseas
Holding Ø
Medtek Asia Private
Limited Ø
Rajshil Investments
Private Limited Ø
Nova Bio-Tech (India)
Limited SUBSIDIARIES o
Satellite Overseas
Holdings Limited – U. K. In which subject holds 1,33,000
Ordinary shares of GBP.1 Each o
IRM Pharmaceuticals
Limited – Sri Lanka In which subject holds 3,39,587
Ordinary shares of Sri Lankan Rs. 10/- each fully paid
up. o
CPL Inc. U.S.A 16020, Swingley Ridge Road, Suite 145,
Chesterfield, MO 63017, USA Tel. (636) 728-1980 Fax. (636) 728-1984 E-mail. contactcpl@cplinc.net Website. http://www.cplinc.net This is wholly owned subsidiary of
company located in Ahmedabad, India was
incorporated in Missouri in March 1999. The
subsidiary’s mission is to provide the North and South
American markets with high quality, high value Pharmaceutical products and services. Subject operates through large sized
premises for Manufacturing facilities at various
locations. o
IRM House – A 5
Stroyed Building, owned by the group, each floor admeasuring approximately
3,600 sq.fts. o
CPL Inc. (Latin
American Division)
318 Indian Trace, PMB 506, Weston, FL 33327, USA Tel. (954) 217-4914 Fax. (954) 217-4915 E-mail. igonzalez@cplinc.net o
Cadila E. A. Limited,
UAE o
Cadila Ethiopia
Limited, Ethiopia |
|
|
|
|
Parent Company |
Ø
Cadila Laboratories
Limited Promoted
by Mr. Indravadan A. Modi and Mr. Ramanbhai B. Patel – Parted in 1996 and
formed their group. Viz. Zydus Group – by the Patels and Cadila
Pharmaceuticals Group by the Modis. (Subject
enjoys approximately Rs. 1 Billion, Term Loan from various Banks and Fis and
Cash Credit Limits / Working Capital Loans from Banks Rs. 671.330 millions.) |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
15000000 |
Equity Shares |
Rs. 10/- |
Rs. 150.000 millions |
|
500000 |
6% Redeemable Preference Shares |
Rs. 100/- |
Rs. 50.000 millions |
|
|
Total |
|
Rs. 300.000 millions |
Issued, Subscribed
& Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
15000000 |
Equity Shares |
Rs. 10/- |
Rs. 150.000 millions |
|
500000 |
6% Redeemable Preference Shares |
Rs. 100/- |
Rs. 50.000 millions |
|
|
Total |
|
Rs. 200.000 millions |
FINANCIAL
DATA
[all figures are in Rupees Millions]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
200.000 |
200.000 |
200.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
918.440 |
785.500 |
642.813 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
NETWORTH
|
1118.440 |
985.500 |
842.813 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1787.169 |
1919.300 |
1971.395 |
|
|
2] Unsecured Loans |
39.210 |
142.800 |
147.187 |
|
TOTAL
BORROWING
|
1826.379 |
2062.100 |
2118.582 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
244.542 |
|
|
|
|
|
|
|
TOTAL
|
3461.690 |
3047.600 |
3205.937 |
|
|
|
|
|
|
|
APPLICATION OF FUNDS
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block]
|
2080.816 |
1893.100 |
1782.255 |
|
Capital work-in-progress
|
0.000 |
0.000 |
157.662 |
|
|
|
|
|
|
|
INVESTMENT
|
116.968 |
115.800 |
115.032 |
|
DEFERREX TAX ASSETS
|
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES
|
|
|
|
|
|
|
Inventories
|
798.240 |
748.300 |
651.601 |
|
|
Sundry Debtors
|
949.850 |
893.200 |
777.474 |
|
|
Cash & Bank Balances
|
58.747 |
28.900 |
90.167 |
|
|
Other Current Assets
|
442.298
|
0.000
|
0.000 |
|
|
Loans & Advances
|
0.000 |
359.800 |
299.267 |
Total Current Assets
|
2249.135
|
2030.200
|
1818.509 |
|
Less : CURRENT LIABILITIES & PROVISIONS
|
|
|
|
|
|
|
Current Liabilities
|
379.587 |
1020.100 |
710.975 |
|
|
Provisions
|
818.087 |
36.100 |
36.925 |
Total Current Liabilities
|
1197.674
|
1056.200
|
747.900 |
|
Net Current
Assets
|
1051.461 |
974.000 |
1070.609 |
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES
|
212.445 |
64.700 |
80.379 |
|
|
|
|
|
|
|
TOTAL
|
3461.690 |
3047.600 |
3205.937 |
|
PROFIT & LOSS ACCOUNT
|
PARTICULARS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
Sales Turnover [including other income]
|
4213.032 |
4531.300 |
4093.709 |
|
|
|
|
|
Profit/(Loss) Before Tax
|
155.295 |
207.400 |
138.969 |
Provision for Taxation
|
0.000 |
43.200 |
34.649 |
Profit/(Loss) After Tax
|
155.295 |
164.200 |
104.320 |
|
|
|
|
|
Export Value
|
NA |
NA |
668.591 |
|
|
|
|
|
Import Value
|
NA |
NA |
170.105 |
|
|
|
|
|
Total Expenditure
|
4057.737 |
4323.900 |
3950.400 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2005 |
31.03.2004 |
31.03.2003 |
PAT / Total Income
|
(%)
|
3.68
|
3.62 |
2.55 |
|
|
|
|
|
|
Net Profit Margin
(PBT/Sales) |
(%) |
3.68
|
4.57 |
3.39 |
|
|
|
|
|
|
Return on Total Assets
(PBT/Total Assets} |
(%) |
3.49
|
5.13 |
3.58 |
|
|
|
|
|
|
Return on Investment (ROI)
(PBT/Networth) |
|
0.14
|
0.21 |
0.16 |
|
|
|
|
|
|
Debt Equity Ratio
(Total Liability/Networth) |
|
4.16
|
4.16 |
4.69 |
|
|
|
|
|
|
Current Ratio
(Current Asset/Current
Liability) |
|
1.87
|
1.92 |
2.43 |
LOCAL AGENCY FURTHER INFORMATION
HISTORY
Subject
was incorporated on 28.02.1991 at Ahmedabad in Gujarat under the name and style
of Nova Biostic (India) Private Limited having Company Registration Number
04-15132.
The
name was changed to the present style w.e.f.: 20.06. 1995
It
became a deemed public liability company w.e.f. : 15.04.1996
Cadila
Pharmaceuticals Limited is a multi product, multi Location Company promoted by
Dr. Indravadan A. Modi and his son Dr. Rajiv I. Modi both doctorates in Biology
and having long years of experience. The company was promoted in the year 1991
and incorporated with Registrar of Companies, Gujarat on 28.02.1991 in the name
of Nova Biostic (India) Private Limited at Sr. No. 04-15132. The name was changed
to Cadila Pharmaceuticals Private Limited on 26.06.1995 and become public
limited company by changing its name to Cadila Pharmaceuticals Limited on
15.04.1996.
In
the year 1995, the earstwhile Cadila Chemicals Limited was amalgamated with
other Cadila group companies viz. Cadila Laboratories, Cadila Antibiotics,
Cadila Exports, Cadila Veterinary etc. Cadila Group restructed and streamlined
its Zydus (Patel Group) and Cadila Pharmaceuticals Limited (Modi Group). Cadila
Pharmaceuticals Limited belings to Modi Group. It has become one of India’s
most respected research based technical savvy Pharmaceutical Company focused on
formulations (Human and Veterinary), New Drug Discovery, Active Pharmaceutical
Ingredients, Analytical Research,
Photochemistry, Biotechnology, Plant Tissue Culture, Bio-Synthetics, Genetic
Engineering, Vaccines and entire gamut of True Life Science today.
The
company has full fledged Research and Development Complex with most modern
equipments at the cost of Rs. 200 millions having 45000 sq. ft. of area and it
is recognized by Department of Science and Technology, Government of India, New
Delhi having about 150 scientists working round the clock.
Milestones
§
State-of-the-art formulations manufacturing facility, built
to the exacting specifications of USFDA, TGA, MCA & MCC.
§
One of the best R & D set-ups in the country, manned by
a 150-strong scientists' pool.
§
Strong Formulations Development base.
§
A host of 'Biotech' products launched, including many
'Firsts in India'.
§
World's First manufacturer of Immuvac- a unique
Immunomodulator.
§
USFDA approvals for Fluoxetine & Ethambutol
manufacturing facilities.
§
ISO 9002 approved Bulk Actives (APIs) manufacturing
facility, offering facilities for contract research.
§
Asia's only manufacturer of 'SULFOLANE' (Tetramethylene
Sulfone).
§
Significant global presence.
§
Leadership in Domestic Marketing and Distribution
Management.
§
Leader in Indian Generics Market.
Diversifications
§
Hospital Disposables including Fiberglass Casting Tape for
the first time in India
§
Diagnostics
§
Laboratory Chemicals
§
Pharmaceutical Machinery Manufacturing
§
Animal Health Formulations & Feed Supplements
§
Agro Business : Plant Tissue Culture and Bio-fertilizers.
§
Information Technology
§
Travel Business
§
Strategic Business Alliances with world-leaders
The company is all set to create new records, scale greater
heights. It has created new world-class production and R&D facilities,
focusing on research, new process innovations leading to patents, and meeting
global standards. The Company always places the common man at its core – who
should be able to access and afford medicines anywhere in the world. For us at
Cadila, this is the only true benchmark of excellence, and the only thing that
really matters.
The
company market their vide range of products through 25 C and S Agents, 1900
Wholesalers, 237318 Pharmacies and 1300 field employees.
The company is in trade terms with :-
Ø
Aditya Chemicals
Ø
Gujarat Microwax Limited
Ø
Gujarat Ampouls Limited
Ø
Nima Packaging
Ø
Vasu Containers
Ø
Yagnesh Printing Press
Profile
Pursuant to its corporate philosophy of striving for
continuous improvement and betterment, the Company has re-located its
manufacturing operations at the state-of-the-art plant at Dholka, located 50 km
from Ahmedabad, the commercial capital of Gujarat. Spread over 44 acres of
verdant, picturesque surroundings, amidst lush green lawns and thick foliage,
the new locale is the most envied pharmaceutical installation in the Asian
sub-continent.
Truly unique in every sense of the term, the Plant’s
standards and facilities can match any other, worldwide. Seven ‘zones of
cleanliness’ have been defined and adhered to, as per the 1997 GMP guidelines
of the European Union. Some of the salient features of the design concepts:
·
No wood or asbestos component.
·
Each zone has separate AHUs (Air
Handling Units), dehumidification unit and dust extraction systems.
·
Segregation of every critical
processing activity in each zone, to avoid cross-contamination.
·
Adherence to stringent specifications
of USFDA, MCA(UK), MCC(South Africa) and TGA (Australia).
·
Respective zones, areas and even
uniforms marked with specific colours of the rainbow (‘Indradhanush’ in the
vernacular), to ensure total segregation.
·
Air environment conditioned in each
area with respect to temperature, humidity, filtration, particle counts, etc.
·
Conformation of each processing stage
with US Federal Standard 209E class of cleanliness; viz. 100, 1,000, 10,000,
100,000 with respect to room air changes, pressure, particle count, flow
direction etc.
·
Duo Pass Reverse Osmosis (RO) water
system, multi-stage distillation plant, self-sanitizing, sanitary SS 31 6L
loops water, water for injection with online monitoring of pH, temperature,
conductivity and TOC requirements as per USP XXIV.
·
Zero-discharge Effluent Treatment Plant
constructed using technology from Advent Integrated System, USA.
·
Environment-friendly VAHP chillers.
·
Rigvent heat extraction devices and
Natural Skylit system in raw material, packing material and finished good
stores.
·
Isolated and dedicated production
facilities for B-Lactum and Cephalosporin dosage forms.
Photochemistry
There has been a growing trend towards natural medicines
and the use of dietary supplements for modern healthcare, as people throughout
the world are becoming increasingly dissatisfied with the possible
side-effects, lack of noticeable long-term results and high cost associated
with allopathic drugs. Herbal products had provided a more natural and often
more effective alternative.
The company uses the ancient Indian medicinal science of Ayurveda to
make herbal formulations with clinically proven efficacy. The Company has an
experienced phytochemistry research team since 1983 and has developed 30 unique
herbal products.
A thorough understanding of the medicinal value of herbs is
achieved in order to work on herbal drugs and to initiate phytochemical
research. Formulation is done through the exact process, as per the ancient
science of Ayurveda.
Phytochemistry Department activities : -
§
Drug development from natural origin
§
Establishment of botanical identity of herbs
§
Phytochemical isolation and identification
§
Screening of herbal formulations and isolated compounds
§
Coordination of clinical pharmacology and clinical trials
§
Development and manufacturing of herbal dietary supplements
§
Analytical Research of & designation of herbs
The complex also houses its own full-fledged R&D
center, set up at a cost of Rs. 200 millions.
The Plant is equipped with modern high-speed machines and
integrated packaging lines to be cost efficient. Extensive use of non-fill
devices, collators, Brevetti visual inspection machines, multi-station tablet
presses, FFS machines, high speed vial/ampoule filler/sealers are some of the
examples.
The plant—with high capacities and scope for future
expansion—is capable of manufacturing all dosage forms viz. Tablets, Capsules,
Liquid Orals, Dry Syrups, Aseptic Liquid and Solid preparations, Sachets etc.
The Group is engaged in many
activities such as formulations, chemicals, CHPL, engineering, agriculture and
telecommunications.
Fixed assets
v Freehold land
v Leasehold land
v Buildings
v Plant & machinery
v Furniture & fixtures
v Office equipments
v Vehicles
Website Details :
CADILA PHARMA TO LAUNCH WORLD'S FIRST
RABEPRAZOLE INTRAVENOUS DOSAGE IN INDIA
The Ahmedabad-based Cadila Pharmaceuticals (CPL) would be launching the first intravenous (IV) dosage form of the anti-ulcerant drug rabeprazole sodium in the world. The company, which introduced the solid dosage of the drug, Rabeloc, for the first time in the country in 2002, has received the DCGI approval to manufacture and market the IV formulation recently.
Rabeprazole sodium, currently the most advanced anti-ulcerant for duodenal ulcers, gastro ulcers and heartburn (gastroesophageal reflux disease -GERD), with the IV dosage form is advised for severe and life threatening ulcer where patient is having upper gastro-intestinal bleeding. The company will be launching the product under the brand name Rabeloc IV shortly in India.
In the gastro segment, Cadila Pharma is currently a leading player with brands such as Aciloc, Lancus, Domperon, Olit, Morsat and others, which enjoy a significant share of the Rs 4450 millions anti-ulcerant market. The company has conducted extensive multicentric clinical trials on rabeprazole at prestigious institutions like AIIMS (All India Institute of Medical Sciences, New Delhi), LTMC (Lokmanya Tilak Medical College, Mumbai), Sion Hospital, Mumbai and V.S. Hospital (Vadilal Sarabhai Hospital), Ahmedabad.
Rabeprazole is an internationally acclaimed molecule, approved by US FDA and WHO under Essential Drugs & Medicine Policy. Currently the drug is available in 21 countries, including US, UK and Japan which is indicated for acid peptic disorders including heartburn (reflux oseophagitis), gastric and duodenal ulcers etc. In the US, rabeprazole is branded as 'Aciphex' and in the rest of the world it is branded as 'Pariet'.
According to company sources, rabeprazole is a blockbuster drug, as compared to the existing anti-ulcerant therapies, in many aspects. It suppresses acid very fast, thereby relieves pain and acidity quickly. Unlike some drugs, which are effective only at day or at night, Rabeloc works in both daytime and nighttime acidity.
As compared to pantaprazole and esomeprazole, which are only approved for heartburn (GERD), Rabeloc is also approved for other disorders including a rare disorder called "Zollinger Ellison Syndrome'. While pantaprazole is approved for short-term therapy (8 weeks therapy), rabeprazole is approved for long-term and short-term therapies and can be safely administered for 52 weeks or more.
CMT REPORT [Corruption, Money laundering & Terrorism]
The
Public Notice information has been collected from various sources including but
not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the
subject of any formal or informal allegations, prosecutions or other official
proceeding for making any prohibited payments or other improper payments to
government officials for engaging in prohibited transactions or with designated
parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Int’l Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.
8] Affiliation
with Government :
No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.
9] Compensation
Package :
Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.
10] Press Report :
No press reports / filings exists on the subject.
CORPORATE
GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a
company’s management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions that
could be included in the agreement with the subject.
FOREIGN
EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.44.56 |
|
UK
Pound |
1 |
Rs.86.16 |
|
Euro |
1 |
Rs.57.76 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
55 |
This score
serves as a reference to assess SC’s credit risk and to set the amount of
credit to be extended. It is calculated from a composite of weighted scores
obtained from each of the major sections of this report. The assessed factors
and their relative weights (as indicated through %) are as follows:
Financial condition (40%) Ownership background (20%) Payment record (10%)
Credit history (10%) Market trend (10%) Operational
size (10%)
RATING
|
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely
sound financial base with the strongest capability for timely payment of
interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate
working capital. No caution needed for credit transaction. It has above
average (strong) capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial &
operational base are regarded healthy. General unfavourable factors will not
cause fatal effect. Satisfactory capability for payment of interest and
principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is
considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable &
favourable factors carry similar weight in credit consideration. Capability
to overcome financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are
apparent. Repayment of interest and principal sums in default or expected to
be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk
exists. Caution needed to be exercised |
Credit not recommended |